Ionis is getting punished for the wrong part of the story. The Wainua miss is real, but the market just knocked nearly 24% off IONS even though the company is in the middle of a more important transition: becoming a broader commercial biotech led by TRYNGOLZA. That shift is already showing up in the numbers, with revenue up 33.9% year over year and the Growth component of the TickerSpark Score sitting at 95. At $64.27, the tape is acting like one partner-program setback erased a multi-launch commercial buildout, and that read looks too bearish.
The cleanest reason the selloff looks overdone is that TRYNGOLZA just became a much bigger product. The FDA approved it on June 24 for severe hypertriglyceridemia, and management said U.S. availability would begin in July. That matters because this was not a maintenance update to an existing niche story; it expanded the addressable market and pushed Ionis further toward a self-driven commercial model.
The commercial engine was already moving before that expansion. In the first quarter, TRYNGOLZA generated $27 million in U.S. net product sales, up from $6 million a year earlier, while total commercial revenue reached $108 million, up 42% year over year. Management also raised its annual olezarsen peak net sales view to more than $3 billion from more than $2 billion. That is the kind of revision that usually gets rewarded, not paired with a collapse that treats the rest of the portfolio as irrelevant.
The broader income statement also says this is not a broken business. Ionis posted $944 million in revenue over the last 12 months, up 33.9%, while EPS growth ran 21.7% year over year. The company has now beaten earnings estimates in seven straight reported quarters, including a 61% surprise in April. Even the TickerSpark Score tells a split story that fits the setup: weak Momentum at 30 because the stock has been hit, but elite Growth at 95 because the operating trajectory is still improving. That disconnect is exactly where contrarian opportunities tend to show up.
The other side has a legitimate point: Wainua was not some throwaway pipeline option. The CARDIO-TTRansform miss hurts a meaningful expansion leg, and WAINUA already contributes economically through royalties. In the first quarter, WAINUA generated $51 million in global sales and $11 million in royalty revenue, so a weaker long-term ATTR-CM thesis deserves a lower valuation than the market assigned before the readout.
The problem with taking that logic all the way to today's price action is that it ignores what is replacing that optionality in the near term. Ionis is no longer just a pipeline promise stock, and the market is trading it like one. Yes, profitability is still ugly, with a -30.9% net margin and a Profitability sub-score of 40, and recent insider selling will not help sentiment. But this is biotech; what matters most is whether commercial assets are scaling fast enough to absorb pipeline shocks, and the current numbers say they are moving in that direction.
That leaves IONS looking more like a reset than a broken thesis. We would treat this as a contrarian name worth respecting on weakness, not chasing blindly, because the stock is clearly damaged technically with an RSI of 31.14 and trading below its 20-, 50- and 200-day averages. Still, when a company with strongly positive recent sentiment, a Buy consensus, and a fresh launch expansion gets repriced this hard on a single setback, the burden shifts to the bears to prove the commercial story is stalling too.
What we'd watch from here is simple: early July rollout traction for TRYNGOLZA in severe hypertriglyceridemia and the next earnings print for proof that commercial revenue keeps compounding. If that 42% commercial growth starts fading, the bear case gets stronger fast. If it holds, this selloff will look like the market anchored to the wrong asset at exactly the wrong time.
